These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25072677)

  • 1. Factors affecting noncompliance with buprenorphine maintenance treatment.
    Fareed A; Eilender P; Ketchen B; Buchanan-Cummings AM; Scheinberg K; Crampton K; Nash A; Shongo-Hiango H; Drexler K
    J Addict Med; 2014; 8(5):345-50. PubMed ID: 25072677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
    Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
    Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
    Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
    Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use.
    Tkacz J; Severt J; Cacciola J; Ruetsch C
    Am J Addict; 2012; 21(1):55-62. PubMed ID: 22211347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
    Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
    McCann DJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
    Bell J; Trinh L; Butler B; Randall D; Rubin G
    Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis.
    Litz M; Leslie D
    Am J Addict; 2017 Dec; 26(8):859-863. PubMed ID: 29143483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel community-based buprenorphine program: client description and initial outcomes.
    Daniels AM; Salisbury-Afshar E; Hoffberg A; Agus D; Fingerhood MI
    J Addict Med; 2014; 8(1):40-6. PubMed ID: 24394496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.